Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors

Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors

In spite of the success of PD-1 blocking antibodies in the clinic their benefits are still restricted to a small fraction of patients. Immune-desert tumors and/or the highly immunosuppressive tumor milieu might hamper the success of PD-1/PD-L1 blocking therapies into a broader range of cancer patien...

Full description

Bibliographic Details
Main Authors: Mario M Soldevilla, Helena Villanueva, Naiara Martinez-Velez, Daniel Meraviglia-Crivelli, Marta M Alonso, Javier Cebollero, Ashwathi P Menon, Montserrat Puigdelloses, Fernando Pastor
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
cancer immunotherapy
b lymphocytes
pd1
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1450711

Internet

http://dx.doi.org/10.1080/2162402X.2018.1450711

Similar Items